| 1 | product pipeline scientific presentations | | | | | | | 2 | 0.86% |
| 2 | is indicated for the | | | | | | | 2 | 0.86% |
| 3 | of the menarini group | | | | | | | 2 | 0.86% |
| 4 | indicated for the treatment | | | | | | | 2 | 0.86% |
| 5 | for the treatment of | | | | | | | 2 | 0.86% |
| 6 | stemline therapeutics home about | | | | | | | 1 | 0.43% |
| 7 | newsmedia stemline is part | | | | | | | 1 | 0.43% |
| 8 | innovative transformative therapies in | | | | | | | 1 | 0.43% |
| 9 | transformative therapies in oncology | | | | | | | 1 | 0.43% |
| 10 | therapies in oncology | | | | | | | 1 | 0.43% |
| 11 | learn more stemline newsmedia | | | | | | | 1 | 0.43% |
| 12 | more stemline newsmedia stemline | | | | | | | 1 | 0.43% |
| 13 | stemline newsmedia stemline is | | | | | | | 1 | 0.43% |
| 14 | is part of the | | | | | | | 1 | 0.43% |
| 15 | stemline is part of | | | | | | | 1 | 0.43% |
| 16 | pipeline of innovative transformative | | | | | | | 1 | 0.43% |
| 17 | part of the menarini | | | | | | | 1 | 0.43% |
| 18 | the menarini group a | | | | | | | 1 | 0.43% |
| 19 | leading international pharmaceutical and | | | | | | | 1 | 0.43% |
| 20 | international pharmaceutical and diagnostics | | | | | | | 1 | 0.43% |
| 21 | pharmaceutical and diagnostics company | | | | | | | 1 | 0.43% |
| 22 | and diagnostics company with | | | | | | | 1 | 0.43% |
| 23 | diagnostics company with a | | | | | | | 1 | 0.43% |
| 24 | turnover of over 4 | | | | | | | 1 | 0.43% |
| 25 | of innovative transformative therapies | | | | | | | 1 | 0.43% |
| 26 | broad pipeline of innovative | | | | | | | 1 | 0.43% |
| 27 | over 4 billion and | | | | | | | 1 | 0.43% |
| 28 | scientific leadership to transform | | | | | | | 1 | 0.43% |
| 29 | learn more our productspipeline | | | | | | | 1 | 0.43% |
| 30 | more our productspipeline at | | | | | | | 1 | 0.43% |
| 31 | our productspipeline at stemline | | | | | | | 1 | 0.43% |
| 32 | productspipeline at stemline we | | | | | | | 1 | 0.43% |
| 33 | are committed to applying | | | | | | | 1 | 0.43% |
| 34 | committed to applying our | | | | | | | 1 | 0.43% |
| 35 | to applying our scientific | | | | | | | 1 | 0.43% |
| 36 | applying our scientific leadership | | | | | | | 1 | 0.43% |
| 37 | our scientific leadership to | | | | | | | 1 | 0.43% |
| 38 | leadership to transform the | | | | | | | 1 | 0.43% |
| 39 | the development of a | | | | | | | 1 | 0.43% |
| 40 | therapeutics home about us | | | | | | | 1 | 0.43% |